<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04356963</url>
  </required_header>
  <id_info>
    <org_study_id>HP - 00090603</org_study_id>
    <nct_id>NCT04356963</nct_id>
  </id_info>
  <brief_title>Adjunct VR Pain Management in Acute Brain Injury</brief_title>
  <official_title>Adjunct Virtual Reality Pain Management in Acute Brain Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe and refractory pain after acute injury is a known-risk factor for chronic opioid use&#xD;
      disorder. In this study, the investigators will use Virtual Reality (VR) immersion as a&#xD;
      non-pharmacological adjunct to treat pain associated with acute traumatic injuries, including&#xD;
      traumatic brain injury. The investigators hypothesize that VR therapy will decrease pain and&#xD;
      reduce opioid use in patients with acute traumatic injuries, including TBI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each participant will undergo one VR session and two control sessions. The VR session will&#xD;
      take place in a VR environment developed in our own Shock Trauma Blended Reality Center and&#xD;
      last 20-30 minutes. The environment is based upon literature reviews on chromotherapy. The&#xD;
      control sessions will include a 2D-tablet based session that mimics the VR content and a&#xD;
      content-less placement of the VR headset. The order of these sessions will be randomized&#xD;
      across patients.&#xD;
&#xD;
      Each participant will complete a pre-study questionnaire to elicit their prior experience&#xD;
      with the virtual reality as well as measures of gaming addiction/engagement, boredom, and&#xD;
      expectancy. These scales will help us determine which patient-level factors predict response&#xD;
      to VR. Before and after each session, participants will complete validated scales of pain,&#xD;
      nausea, and anxiety.. Pre- and Post-VR opioid use will be recorded. Basic vital signs&#xD;
      including heart rate, blood pressure, and respiratory rate, will be recorded before and after&#xD;
      each session to monitor autonomic response. Advanced measures of autonomic response will&#xD;
      include heart rate variability, galvanic skin response, and pupillometry metrics. At the&#xD;
      conclusion of all sessions, participants will complete another questionnaire to document&#xD;
      their subjective experience of using VR.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 5, 2020</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Within-Subjects Design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
    <masking_description>Interventions will take place in patient rooms with curtain pulled and sign to mask active intervention vs. control intervention from care providers.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pain Score</measure>
    <time_frame>Pre- and Post-Intervention (approximately 30 minutes)</time_frame>
    <description>Pre- vs. Post-Intervention Ratings on Numeric Pain Rating Scale. Numeric Pain Rating scale range is from 0 (no pain) -10 (severe pain)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opioid Administration</measure>
    <time_frame>6 hours</time_frame>
    <description>DIchotomized outcome of whether or not participant received opioid following intervention</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Nausea</measure>
    <time_frame>Pre- and Post-Intervention (approximately 30 minutes)</time_frame>
    <description>Pre- vs. Post-Intervention Ratings on Numeric Rating Scale for Nausea. Numeric Rating Scale for Nausea ranges from 0 (no nausea) - 10 (worst nausea possible)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Anxiety</measure>
    <time_frame>Pre- and Post-Intervention (approximately 30 minutes)</time_frame>
    <description>Pre- vs. Post-Intervention Anxiety Ratings from Short-Form State Anxiety Inventory. Scores Range from 6 (Not at all anxious) - 24 (Very much amxious)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Galvanic Skin Response</measure>
    <time_frame>Pre- and Post-Intervention (approximately 30 minutes)</time_frame>
    <description>Pre- vs. Post-Intervention Galvanic Skin Response. Galvanic Skin Response is measured in micro-Siemens with increasing response reflecting increased emotional arousal.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Heart Rate Variability</measure>
    <time_frame>Pre- and Post-Intervention (approximately 30 minutes)</time_frame>
    <description>Pre- vs. Post-Intervention Heart Rate Variability. Decreasing HRV indices are associated with the activity of sympathetic system, while increasing of the HRV indices are associated with the activity of parasympathetic nervous system</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in pupillometry</measure>
    <time_frame>Pre- and Post-Intervention (approximately 30 minutes)</time_frame>
    <description>Pre- vs. Post-Intervention Pupillary Maximum Constriction Velocity. Reduced pupillary maximum constriction velocity is representative of decreased parasympathetic nervous system activity.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subjective Measures of VR experience</measure>
    <time_frame>Pre- and Post-study (approximately 2-3 days)</time_frame>
    <description>A Likert-Scale questionnaire will be used to assess participant's subjective ratings of how fun, immersive/engaging, and calming the interventional sessions were. The scales rang from 0 (not at all) to 5 (very much). They will also rate how likely they would be to recommend the sessiosn to another participant with their problem (0 (very unlikely) to 5 (very likely))</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <condition>Headaches Posttraumatic</condition>
  <condition>Trauma</condition>
  <condition>Pain, Acute</condition>
  <arm_group>
    <arm_group_label>Virtual Reality Sessions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will participate in virtual reality sessions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator Sessions</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All participants will participate in tablet-based sessions to content-less sessions wearing the virtual reality headset</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Virtual Reality Session</intervention_name>
    <description>20-30 minute session of virtual reality immersive content.</description>
    <arm_group_label>Virtual Reality Sessions</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Tablet-based Session</intervention_name>
    <description>20-30 minute session of tablet-based content that mimics the content from virtual reality sessions.</description>
    <arm_group_label>Comparator Sessions</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Use of Virtual Reality Head Mounted Display without Content</intervention_name>
    <description>20-30 minutes session using head mounted display to reduce light and sound.</description>
    <arm_group_label>Comparator Sessions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Traumatic Injury (including but not limited to traumatic brain injury)&#xD;
&#xD;
          -  Age greater than or equal to 18 years-old&#xD;
&#xD;
          -  Endorsing at least moderate pain as defined by documentation of at least one numeric&#xD;
             rating pain scale score of 3 or more in the last 24 hours.&#xD;
&#xD;
          -  Glasgow Coma Scale of 15&#xD;
&#xD;
          -  Expected to stay in the hospital for at least 12 hours after enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Seizure prior to enrollment&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  non-English speaking&#xD;
&#xD;
          -  Known intolerance of Virtual Reality&#xD;
&#xD;
          -  Patient unable to consent for themselves&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas A Morris, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, College Park</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicholas A Morris, MD</last_name>
    <phone>410-328-4515</phone>
    <email>Nicholas.Morris@som.umaryland.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah B Murthi, MD</last_name>
    <email>SMurthi@som.umaryland.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>R Adams Cowley Shock Trauma Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Murthi, M.D.</last_name>
      <email>SMurthi@som.umaryland.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas A Morris, MD</last_name>
      <phone>410-328-9423</phone>
      <email>nicholas.morris@som.umaryland.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 19, 2020</study_first_submitted>
  <study_first_submitted_qc>April 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Nicholas Morris</investigator_full_name>
    <investigator_title>Assistant Professor of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Post-Traumatic Headache</mesh_term>
    <mesh_term>Headache</mesh_term>
    <mesh_term>Acute Pain</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 15, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT04356963/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

